 populations at high risk for cardiovascular disease. Whether these findings can be generalized to the general population of people with diabetes, we don't have enough evidence to make that statement. I think because this was meant to look at the outcomes, perhaps those nuances of the populations, which are important for applicability to real-world care, may not have been detailed. Kalyani notes that newer medicines are much more expensive. At Johns Hopkins, I'm Elizabeth Tracy.